Cardinal Health Appoints New Board Chair
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CAH?
Source: PRnewswire
- Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, marking a significant governance shift aimed at continuing the execution of strategic priorities.
- Rich Leadership Experience: Hemingway Hall has been on the Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing valuable governance and strategic knowledge from her extensive background in the healthcare sector.
- Ongoing Strategic Execution: CEO Jason Hollar expressed anticipation for Hemingway Hall to continue Kenny's legacy, focusing on strong governance and long-term value creation, ensuring the company maintains its competitive edge in future market conditions.
- Earnings Release Preview: Cardinal Health plans to release its third-quarter fiscal 2026 earnings on April 30, with management expressing confidence in the outlook for fiscal 2026, demonstrating the company's resilience in an uncertain market environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAH
Wall Street analysts forecast CAH stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 210.920
Low
209.00
Averages
225.18
High
244.00
Current: 210.920
Low
209.00
Averages
225.18
High
244.00
About CAH
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardinal Health Appoints New Board Chair
- Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, who has served since 2007 and as Chairman since 2018, during which he supported the company through significant transformations in strategic portfolio evolution and operational improvements.
- Experienced Leadership: Hemingway Hall has been on the Cardinal Health Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing extensive healthcare leadership experience and deep institutional knowledge that will aid in executing the company's strategic priorities.
- Positive Financial Outlook: The company is set to release its third-quarter fiscal 2026 earnings on April 30, maintaining confidence in its fiscal 2026 outlook, which indicates stability and growth potential in the current market environment.
- Commitment to Continuous Improvement: Cardinal Health emphasizes a customer-centric approach, striving for operational efficiency through innovative solutions that enhance lives, showcasing its leadership position in the distribution and services of healthcare products.
See More
Cardinal Health Appoints New Board Chair
- Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, marking a significant governance shift aimed at continuing the execution of strategic priorities.
- Rich Leadership Experience: Hemingway Hall has been on the Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing valuable governance and strategic knowledge from her extensive background in the healthcare sector.
- Ongoing Strategic Execution: CEO Jason Hollar expressed anticipation for Hemingway Hall to continue Kenny's legacy, focusing on strong governance and long-term value creation, ensuring the company maintains its competitive edge in future market conditions.
- Earnings Release Preview: Cardinal Health plans to release its third-quarter fiscal 2026 earnings on April 30, with management expressing confidence in the outlook for fiscal 2026, demonstrating the company's resilience in an uncertain market environment.
See More
Stock Market Declines Amid Rising Inflation and Geopolitical Tensions
- Market Decline: The S&P 500, Nasdaq, and Dow have experienced their fourth consecutive week of losses, with declines of 1.5% and approximately 2% respectively, reflecting investor concerns over economic outlook amid the Iran war and rising wholesale inflation.
- Inflation Concerns: The producer price index rose 0.7% in February, significantly above the expected 0.3%, with Fed Chair Jerome Powell indicating that inflation is not decreasing as hoped, and the spike in oil prices is expected to exacerbate this trend, creating a 'one-two punch' for the market.
- Memory Shortage Impact: Micron reported nearly tripled revenue but cited structural supply constraints, with CEO stating they can only meet 50% to two-thirds of major customers' needs, leading to increased pressure on hardware companies from rising memory costs.
- Nvidia GTC Highlights: Nvidia's GTC conference revealed expectations of $1 trillion in orders for Blackwell and Vera Rubin chips by 2027, yet the stock fell 4% despite positive announcements, indicating a complex market reaction to AI chip demand.
See More
Market Continues Decline, Energy Sector Shows Strength
- Market Weakness: The S&P 500 is on track for its fourth consecutive week of losses, pulling back approximately 6% from its closing high on January 27 and down over 4% year-to-date, indicating a decline in market confidence and investor sentiment.
- Energy Sector Strength: Despite the overall market downturn, the energy sector gained about 4% this week, extending its year-to-date increase to 33%, highlighting the sector's resilience and growth potential amid inflationary pressures.
- Rising Bond Yields: The yield on the 10-Year Treasury surged roughly 10 basis points to 4.38%, marking its highest level since last July, as expectations for interest rate hikes before the year's end intensify, potentially exerting further pressure on the stock market.
- Optimistic Outlook for Honeywell: Although Honeywell's stock declined this week with the CEO indicating first-quarter revenue will be light, the company maintains a positive full-year guidance and plans to host an investor day for its aerospace division in June, which is expected to boost stock performance as the spin-off date approaches.
See More
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
- Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
- Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
- Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
- Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
See More
Stocks Decline as Oil Prices Surge Following Iran's Attack
- Oil Price Surge Impact: Stocks fell as Brent crude briefly hit $119 per barrel following Iran's attack on a key LNG facility in Qatar, causing the S&P 500 to slip below its 200-day moving average for the first time since last May, raising concerns among long-term investors.
- Eli Lilly Drug Study Update: Eli Lilly reported that its Phase 3 study of retatrutide for type 2 diabetes showed superior weight loss compared to Mounjaro over 40 weeks, yet the stock remained stagnant as investors are more focused on the anticipated approval of its new GLP-1 pill next month.
- Nvidia Stock Analysis: Jim Cramer reiterated his
See More
Cardinal Health Appoints New Board Chair
- Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, who has served since 2007 and as Chairman since 2018, during which he supported the company through significant transformations in strategic portfolio evolution and operational improvements.
- Experienced Leadership: Hemingway Hall has been on the Cardinal Health Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing extensive healthcare leadership experience and deep institutional knowledge that will aid in executing the company's strategic priorities.
- Positive Financial Outlook: The company is set to release its third-quarter fiscal 2026 earnings on April 30, maintaining confidence in its fiscal 2026 outlook, which indicates stability and growth potential in the current market environment.
- Commitment to Continuous Improvement: Cardinal Health emphasizes a customer-centric approach, striving for operational efficiency through innovative solutions that enhance lives, showcasing its leadership position in the distribution and services of healthcare products.
See More
Cardinal Health Appoints New Board Chair
- Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, marking a significant governance shift aimed at continuing the execution of strategic priorities.
- Rich Leadership Experience: Hemingway Hall has been on the Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing valuable governance and strategic knowledge from her extensive background in the healthcare sector.
- Ongoing Strategic Execution: CEO Jason Hollar expressed anticipation for Hemingway Hall to continue Kenny's legacy, focusing on strong governance and long-term value creation, ensuring the company maintains its competitive edge in future market conditions.
- Earnings Release Preview: Cardinal Health plans to release its third-quarter fiscal 2026 earnings on April 30, with management expressing confidence in the outlook for fiscal 2026, demonstrating the company's resilience in an uncertain market environment.
See More
Stock Market Declines Amid Rising Inflation and Geopolitical Tensions
- Market Decline: The S&P 500, Nasdaq, and Dow have experienced their fourth consecutive week of losses, with declines of 1.5% and approximately 2% respectively, reflecting investor concerns over economic outlook amid the Iran war and rising wholesale inflation.
- Inflation Concerns: The producer price index rose 0.7% in February, significantly above the expected 0.3%, with Fed Chair Jerome Powell indicating that inflation is not decreasing as hoped, and the spike in oil prices is expected to exacerbate this trend, creating a 'one-two punch' for the market.
- Memory Shortage Impact: Micron reported nearly tripled revenue but cited structural supply constraints, with CEO stating they can only meet 50% to two-thirds of major customers' needs, leading to increased pressure on hardware companies from rising memory costs.
- Nvidia GTC Highlights: Nvidia's GTC conference revealed expectations of $1 trillion in orders for Blackwell and Vera Rubin chips by 2027, yet the stock fell 4% despite positive announcements, indicating a complex market reaction to AI chip demand.
See More
Market Continues Decline, Energy Sector Shows Strength
- Market Weakness: The S&P 500 is on track for its fourth consecutive week of losses, pulling back approximately 6% from its closing high on January 27 and down over 4% year-to-date, indicating a decline in market confidence and investor sentiment.
- Energy Sector Strength: Despite the overall market downturn, the energy sector gained about 4% this week, extending its year-to-date increase to 33%, highlighting the sector's resilience and growth potential amid inflationary pressures.
- Rising Bond Yields: The yield on the 10-Year Treasury surged roughly 10 basis points to 4.38%, marking its highest level since last July, as expectations for interest rate hikes before the year's end intensify, potentially exerting further pressure on the stock market.
- Optimistic Outlook for Honeywell: Although Honeywell's stock declined this week with the CEO indicating first-quarter revenue will be light, the company maintains a positive full-year guidance and plans to host an investor day for its aerospace division in June, which is expected to boost stock performance as the spin-off date approaches.
See More
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
- Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
- Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
- Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
- Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
See More
Stocks Decline as Oil Prices Surge Following Iran's Attack
- Oil Price Surge Impact: Stocks fell as Brent crude briefly hit $119 per barrel following Iran's attack on a key LNG facility in Qatar, causing the S&P 500 to slip below its 200-day moving average for the first time since last May, raising concerns among long-term investors.
- Eli Lilly Drug Study Update: Eli Lilly reported that its Phase 3 study of retatrutide for type 2 diabetes showed superior weight loss compared to Mounjaro over 40 weeks, yet the stock remained stagnant as investors are more focused on the anticipated approval of its new GLP-1 pill next month.
- Nvidia Stock Analysis: Jim Cramer reiterated his
See More
